§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇲🇾Malaysia	🇺🇸United States
Authority & dossier
Regulatory authority	NPRA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +5	—
Lead pathway (timeline & fees) — Full Evaluation — New Drug Product (NCE / new biologic) · New Drug Application — 505(b)(1)
Pathway name	Full Evaluation — New Drug Product (NCE / new biologic)	New Drug Application — 505(b)(1)
Approval timeline	245–365 days	304–365 days
Application fee	MYR 1,000	USD 4,310,002
Annual renewal	MYR 500	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	PRHs must designate a registered pharmacist (under the Registration of Pharmacists Act 1951) as the responsible person for the licensed premises, and a Qualified Person for Pharmacovigilance (QPPV) who is the contact for NPRA's Pharmacovigilance Section.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	2 designations	6 designations
Examples	Facilitated Registration Pathway (FRP), Conditional Registration / Public Health Emergency	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified per the DRGD into Major Variation (MaV — DCA approval), Minor Variation (MiV-PA prior approval, MiV-N notification) and Administrative Variation. Aligned with ASEAN Variation Guideline.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Drug registration is valid for 5 years and must be renewed before expiry, with up-to-date CMC, safety and labelling information.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	NPRA's Pharmacovigilance Section coordinates national ADR reporting (Malaysia is a member of the WHO Programme for International Drug Monitoring, Uppsala). PRHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances. NPRA publishes safety alerts via MADRAC (Malaysian Adverse Drug Reactions Advisory Committee).	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–60 days	30–30 days
GCP standard	ICH E6(R2/R3) GCP; Malaysian Guideline for Good Clinical Practice	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Free pricing	Free pricing
Reference pricing	No	No
HTA required	Yes	No
HTA body	MaHTAS — Malaysian Health Technology Assessment Section, Ministry of Health	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

MalaysiaNPRA
United StatesFDA

English submissions

MalaysiaYes
United StatesYes

CTD accepted

MalaysiaYes
United StatesYes

eCTD accepted

MalaysiaYes
United StatesYes

Reliance pathway

MalaysiaAvailable
United StatesNone

Reference agencies

MalaysiaFDA (US), EMA, MHRA (UK), Health Canada +5
United States—

Lead pathway (timeline & fees) — Full Evaluation — New Drug Product (NCE / new biologic) · New Drug Application — 505(b)(1)

Pathway name

MalaysiaFull Evaluation — New Drug Product (NCE / new biologic)
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Malaysia245–365 days
United States304–365 days

Application fee

MalaysiaMYR 1,000
United StatesUSD 4,310,002

Annual renewal

MalaysiaMYR 500
United StatesUSD 416,734

Local representative

MalaysiaRequired
United StatesNot required

Local manufacturing

MalaysiaNot required
United StatesNot required

GMP inspection

MalaysiaRequired
United StatesRequired

MAH & local presence

Local entity required

MalaysiaYes
United StatesNo

Local responsible person

MalaysiaYes
United StatesYes

RP role

MalaysiaPRHs must designate a registered pharmacist (under the Registration of Pharmacists Act 1951) as the responsible person for the licensed premises, and a Qualified Person for Pharmacovigilance (QPPV) who is the contact for NPRA's Pharmacovigilance Section.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Malaysia2 designations
United States6 designations

Examples

MalaysiaFacilitated Registration Pathway (FRP), Conditional Registration / Public Health Emergency
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

MalaysiaVariations classified per the DRGD into Major Variation (MaV — DCA approval), Minor Variation (MiV-PA prior approval, MiV-N notification) and Administrative Variation. Aligned with ASEAN Variation Guideline.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

MalaysiaDrug registration is valid for 5 years and must be renewed before expiry, with up-to-date CMC, safety and labelling information.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

MalaysiaNPRA's Pharmacovigilance Section coordinates national ADR reporting (Malaysia is a member of the WHO Programme for International Drug Monitoring, Uppsala). PRHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances. NPRA publishes safety alerts via MADRAC (Malaysian Adverse Drug Reactions Advisory Committee).
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

MalaysiaAvailable
United StatesAvailable

Compassionate Use

MalaysiaAvailable
United StatesAvailable

Emergency Import

MalaysiaAvailable
United StatesAvailable

Parallel Import

MalaysiaNot permitted
United StatesNot permitted

Clinical trials

CTA approval

MalaysiaRequired
United StatesRequired

Ethics approval

MalaysiaYes
United StatesYes

CTA timeline

Malaysia30–60 days
United States30–30 days

GCP standard

MalaysiaICH E6(R2/R3) GCP; Malaysian Guideline for Good Clinical Practice
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

MalaysiaFree pricing
United StatesFree pricing

Reference pricing

MalaysiaNo
United StatesNo

HTA required

MalaysiaYes
United StatesNo

HTA body

MalaysiaMaHTAS — Malaysian Health Technology Assessment Section, Ministry of Health
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding